O	0	9	Adherence
O	10	12	to
O	13	14	a
O	15	19	long
O	19	20	-
O	20	24	term
B-intervention	25	36	progressive
I-intervention	37	47	resistance
I-intervention	48	56	training
I-intervention	57	64	program
O	64	65	,
O	66	75	combining
O	76	86	supervised
O	87	90	and
O	91	95	home
O	95	96	-
O	96	101	based
O	102	110	exercise
O	111	114	for
O	115	121	breast
O	122	128	cancer
O	129	137	patients
O	138	144	during
O	145	153	adjuvant
O	154	163	treatment
O	163	164	.

O	165	175	Background
O	175	176	:
O	177	180	The
O	181	188	purpose
O	189	191	of
O	192	195	the
O	196	201	study
O	202	205	was
O	206	208	to
O	209	216	examine
O	217	226	adherence
O	227	230	and
O	231	239	identify
O	240	247	patient
O	247	248	-
O	249	252	and
O	253	262	treatment
O	262	263	-
O	263	270	related
O	271	278	factors
O	279	289	associated
O	290	294	with
O	295	304	adherence
O	305	307	to
O	308	309	a
O	310	312	20
O	312	313	-
O	313	317	week
O	318	326	combined
O	327	337	supervised
O	338	341	and
O	342	346	home
O	346	347	-
O	347	352	based
O	353	364	progressive
O	365	375	resistance
O	376	384	training
O	385	392	program
O	393	395	in
O	396	401	women
O	402	409	treated
O	410	413	for
O	414	420	breast
O	421	427	cancer
O	427	428	.

O	429	440	Methodology
O	440	441	:
O	442	445	The
O	446	451	study
O	452	462	population
O	463	472	consisted
O	473	475	of
O	476	479	the
O	480	492	intervention
O	493	498	group
O	499	501	in
O	502	503	a
O	504	514	randomized
O	515	523	clinical
O	524	529	trial
O	530	539	examining
O	540	543	the
O	544	550	effect
O	551	553	of
O	554	564	resistance
O	565	573	exercise
O	574	576	on
B-condition	577	588	lymphoedema
O	589	599	prevention
O	600	601	(
O	601	602	n
O	603	604	=
B-total-participants	605	607	82
O	607	608	)
O	608	609	.

O	610	613	The
O	614	618	full
O	619	626	program
O	627	633	lasted
O	634	636	50
O	637	642	weeks
O	642	643	,
O	644	648	with
O	649	651	an
O	652	659	initial
O	660	662	20
O	663	668	weeks
O	669	677	combined
O	678	688	supervised
O	689	692	and
O	693	697	home
O	697	698	-
O	698	703	based
O	704	712	exercise
O	713	721	followed
O	722	724	by
O	725	727	30
O	728	733	weeks
O	734	738	self
O	738	739	-
O	739	751	administered
O	752	760	exercise
O	760	761	.

O	762	773	Information
O	774	779	about
O	780	790	attendance
O	791	796	rates
O	797	798	(
O	798	808	supervised
O	809	817	exercise
O	817	818	)
O	819	822	and
B-control	823	831	exercise
I-control	832	839	dairies
O	840	841	(
O	841	845	home
O	845	846	-
O	846	851	based
O	852	860	exercise
O	860	861	)
O	862	864	in
O	865	868	the
O	869	874	first
O	875	877	20
O	878	883	weeks
O	884	887	was
O	888	897	available
O	898	901	for
O	902	904	74
O	905	908	and
O	909	911	62
O	912	924	participants
O	924	925	,
O	926	938	respectively
O	938	939	.

O	940	949	Adherence
O	950	953	was
O	954	962	measured
O	963	965	as
O	966	973	numbers
O	974	976	of
O	977	985	exercise
O	986	994	sessions
O	995	1004	performed
O	1005	1012	divided
O	1013	1015	by
O	1016	1024	expected
O	1025	1031	number
O	1032	1034	of
O	1035	1043	exercise
O	1044	1052	sessions
O	1053	1057	with
O	1058	1059	>
O	1059	1060	2
O	1060	1061	/
O	1061	1062	3
O	1063	1074	categorized
O	1075	1077	as
O	1078	1082	high
O	1083	1092	adherence
O	1092	1093	.

O	1094	1097	Age
O	1097	1098	-
O	1098	1106	adjusted
O	1107	1111	odds
O	1112	1118	ratios
O	1119	1120	(
O	1120	1122	OR
O	1122	1123	)
O	1124	1128	were
O	1129	1133	used
O	1134	1136	to
O	1137	1143	assess
O	1144	1147	the
O	1148	1160	associations
O	1161	1168	between
O	1169	1176	patient
O	1176	1177	-
O	1178	1181	and
O	1182	1191	treatment
O	1191	1192	-
O	1192	1199	related
O	1200	1207	factors
O	1208	1212	with
O	1213	1222	adherence
O	1222	1223	.

O	1224	1231	Results
O	1231	1232	:
O	1233	1236	The
O	1237	1243	number
O	1244	1246	of
O	1247	1259	participants
O	1260	1264	with
O	1265	1269	high
B-outcome	1270	1279	adherence
I-outcome	1280	1282	to
I-outcome	1283	1293	supervised
I-outcome	1294	1302	exercise
O	1303	1312	decreased
O	1313	1315	in
O	1316	1319	the
O	1320	1324	late
O	1325	1331	period
O	1332	1333	(
O	1333	1337	from
O	1338	1342	week
O	1343	1345	11
O	1346	1352	onward
O	1352	1353	)
O	1354	1362	compared
O	1363	1365	to
O	1366	1369	the
O	1370	1375	early
O	1376	1382	period
O	1383	1384	(
O	1384	1386	65
O	1386	1387	%
O	1388	1390	vs
O	1390	1391	.
O	1392	1394	48
O	1394	1395	%
O	1395	1396	)
O	1397	1404	whereas
O	1405	1408	the
O	1409	1419	proportion
O	1420	1422	of
O	1423	1435	participants
O	1436	1440	with
O	1441	1445	high
B-outcome	1446	1455	adherence
I-outcome	1456	1458	to
I-outcome	1459	1463	home
I-outcome	1463	1464	-
I-outcome	1464	1469	based
I-outcome	1470	1478	exercise
O	1479	1487	remained
O	1488	1493	close
O	1494	1496	to
O	1497	1499	55
O	1499	1500	%
O	1500	1501	.

O	1502	1505	The
O	1506	1510	most
O	1511	1520	prominent
O	1521	1527	factor
O	1528	1538	associated
O	1539	1543	with
O	1544	1548	high
B-outcome	1549	1558	adherence
I-outcome	1559	1561	to
I-outcome	1562	1572	supervised
I-outcome	1573	1581	exercise
O	1582	1585	was
O	1586	1597	neoadjuvant
O	1598	1610	chemotherapy
O	1611	1612	[
O	1612	1614	OR
O	1615	1616	7
O	1616	1617	.
O	1617	1619	09
O	1619	1620	;
O	1621	1623	95
O	1623	1624	%
O	1625	1635	confidence
O	1636	1644	interval
O	1645	1646	(
O	1646	1648	CI
O	1648	1649	)
O	1649	1650	,
O	1651	1652	1
O	1652	1653	.
O	1653	1655	12
O	1655	1656	-
O	1656	1658	44
O	1658	1659	.
O	1659	1661	62
O	1661	1662	]
O	1662	1663	.

O	1664	1667	For
O	1668	1672	home
O	1672	1673	-
O	1673	1678	based
O	1679	1687	exercise
O	1687	1688	,
O	1689	1694	lower
B-outcome	1695	1704	adherence
O	1705	1708	was
O	1709	1713	seen
B-outcome	1714	1716	in
I-outcome	1717	1722	obese
I-outcome	1723	1735	participants
O	1736	1737	(
O	1737	1739	OR
O	1740	1741	0
O	1741	1742	.
O	1742	1744	16
O	1744	1745	;
O	1746	1748	95
O	1748	1749	%
O	1750	1752	CI
O	1752	1753	,
O	1754	1755	0
O	1755	1756	.
O	1756	1758	04
O	1758	1759	-
O	1759	1760	0
O	1760	1761	.
O	1761	1763	65
O	1763	1764	)
O	1765	1768	and
B-outcome	1769	1771	in
I-outcome	1772	1784	participants
I-outcome	1785	1789	with
I-outcome	1790	1797	average
I-outcome	1798	1800	or
I-outcome	1801	1806	below
I-outcome	1807	1814	average
I-outcome	1815	1820	lower
I-outcome	1821	1825	body
I-outcome	1826	1832	muscle
I-outcome	1833	1841	strength
O	1842	1844	at
O	1845	1853	baseline
O	1854	1855	(
O	1855	1857	OR
O	1858	1859	0
O	1859	1860	.
O	1860	1862	12
O	1862	1863	;
O	1864	1866	95
O	1866	1867	%
O	1868	1870	CI
O	1870	1871	,
O	1872	1873	0
O	1873	1874	.
O	1874	1876	03
O	1876	1877	-
O	1877	1878	0
O	1878	1879	.
O	1879	1881	46
O	1881	1882	)
O	1882	1883	.

O	1884	1894	Conclusion
O	1894	1895	:
O	1896	1899	The
O	1900	1907	results
O	1908	1910	of
O	1911	1915	this
O	1916	1921	study
O	1922	1927	offer
O	1928	1936	valuable
O	1937	1948	information
O	1949	1951	on
O	1952	1959	factors
O	1960	1970	associated
O	1971	1975	with
O	1976	1985	adherence
O	1986	1988	to
O	1989	1990	a
O	1991	1998	program
O	1999	2001	of
O	2002	2012	supervised
O	2013	2016	and
O	2017	2021	home
O	2021	2022	-
O	2022	2027	based
O	2028	2036	exercise
O	2036	2037	.

O	2038	2051	Interventions
O	2052	2055	may
O	2056	2058	be
O	2059	2066	adapted
O	2067	2069	to
O	2070	2076	ensure
O	2077	2083	higher
O	2084	2093	adherence
O	2094	2099	rates
O	2100	2107	through
O	2108	2118	supportive
O	2119	2126	efforts
O	2127	2135	targeted
O	2136	2138	to
O	2139	2144	women
O	2145	2148	who
O	2149	2152	are
O	2153	2158	obese
O	2158	2159	,
O	2160	2164	have
O	2165	2168	low
O	2169	2175	muscle
O	2176	2184	strength
O	2185	2188	and
O	2189	2192	who
O	2193	2200	receive
O	2201	2203	no
O	2204	2206	or
O	2207	2215	adjuvant
O	2216	2228	chemotherapy
O	2229	2230	(
O	2230	2232	as
O	2233	2240	opposed
O	2241	2243	to
O	2244	2255	neoadjuvant
O	2256	2268	chemotherapy
O	2268	2269	)
O	2270	2276	during
O	2277	2285	exercise
O	2285	2286	.
